• 1

    Scher RK: Onychomycosis: a significant medical disorder. .J Am Acad Dermatol 35 (3 pt 2)::S2. ,1996. .

  • 2

    Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. .J Am Acad Dermatol 38 (5 pt 1)::702. ,1998. .

  • 3

    Lubeck DP, Patrick DL, McNulty P, et al: Quality of life of persons with onychomycosis. .Qual Life Res 2::341. ,1993. .

  • 4

    Arenas R, Dominguez-Cherit J, Fernandez LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. .Int J Dermatol 34::138. ,1996. .

    • Search Google Scholar
    • Export Citation
  • 5

    Bräutigam M, Nolting S, Schopf RE, et al: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. .BMJ 311::919. ,1995. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Arikian SR, Einarson TR, Kobelt-Nguyen G, et al: A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. .Br J Dermatol 130 (suppl 43)::35. ,1994. .

    • Search Google Scholar
    • Export Citation
  • 7

    Marchetti A, Piech CT, McGhan WF, et al: Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. .Clin Ther 18::757. ,1996. .

  • 8

    Stier DM, Henke C, Schein J, et al: Cost of treatment for onychomycosis: data from a 9-month observational study. .Pharmacoeconomics 19::267. ,2001. .

  • 9

    Schein JR, Gause D, Stier DM, et al: Onychomycosis: baseline results of an observational study. .JAPMA 87::512. ,1997. .

  • 10

    Stewart AL, Ware JE, Jr (eds): Measuring Functioning and Well-Being: The Medical Outcomes Study Approach, Duke University Press, Durham NC, 1992..

    • Crossref
    • Export Citation
  • 11

    Ware JE, Snow KK, Kosinki M, et al: SF-36 Health Survey: Manual and Interpretation Guide, The Health Institute, New England Medical Center, Boston, 1993..

  • 12

    Lubeck DP, Gause D, Schein JR, et al: A health-related quality of life measure for use in patients with onychomycosis: a validation study. .Qual Life Res 8::121. ,1999. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Barnett DB: Assessment of quality of life. .Am J Cardiol 67::41C. ,1991. .

  • 14

    Drake L: Quality of life issues for patients with fungal nail infections. .AIDS Patient Care 9 (suppl 1)::15. ,1995. .

  • 15

    Chiritescu MM, Chiritescu ME, Scher RK: Newer systemic antifungal drugs for the treatment of onychomycosis. .Clin Podiatr Med Surg 13::741. ,1996. .

  • 16

    Faergemann J, Zehender H, Boukhabza A, et al: A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication [letter]. .Acta Derm Venereol 77::74. ,1996. .

    • Search Google Scholar
    • Export Citation
  • 17

    van der Schroeff JG, Cirkel PKS, Crijns MB, et al: A randomized treatment duration-finding study of terbinafine in onychomycosis. .Br J Dermatol 126 (suppl)::36. ,1992. .

    • Search Google Scholar
    • Export Citation
  • 18

    Svejgaard EL, Brandrup F, Kragballe K, et al: Oral terbinafine in toenail dermatophytosis: a double-blind, placebo-controlled multicenter study with 12 months’ follow-up. .Acta Derm Venereol 77::66. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Elewski BE: Diagnostic techniques for confirming onychomycosis. .J Am Acad Dermatol 35 (3 pt 2)::S6. 1996. .

Patient Satisfaction with Oral versus Nonoral Therapeutic Approaches in Onychomycosis

View More View Less
  • 1 Submitted as Vice President, The Lewin Group, San Francisco, CA.
  • | 2 Assistant Director, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp, East Hanover, NJ.
  • | 3 Submitted as Associate Professor of Medicine and Chief, Infectious Diseases, Pennsylvania College of Podiatric Medicine, Philadelphia, PA.
  • | 4 Submitted as Executive Director, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp, East Hanover, NJ. Mailing address: Janssen Pharmaceutica, Inc, 1125 Trenton-Harbourton Roads, Titusville, NJ 08580.
  • | 5 Submitted as Project Director, The Lewin Group, San Francisco, CA.
  • | 6 Submitted as Database Manager/Analyst, The Lewin Group, San Francisco, CA.
  • | 7 Submitted as Outcomes Research Manager, Novartis Pharmaceuticals Corp, East Hanover, NJ.
Restricted access

The follow-up results of a 9-month observational study of 150 onychomycosis patients treated with a variety of mechanical, topical, and oral therapies by podiatric physicians and dermatologists are presented. Changes from baseline in toenail condition and patient satisfaction were assessed at 4- and 9-month follow-up. At 9 months, patients who had received oral therapy reported significantly fewer onychomycosis-related problems in social situations, including embarrassment or self-consciousness about the appearance of nails, avoidance of contact by others, being perceived as unclean or untidy, and the desire to keep their nails concealed. Patient-reported satisfaction with the treatment program was significantly higher for those receiving oral therapy than for those receiving nonoral therapy. (J Am Podiatr Med Assoc 91(10): 521-527, 2001)

This study was underwritten by Novartis Pharmaceuticals Corp, East Hanover, NJ.